The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations

被引：36
|
作者：
Tiacci, E. [1 ]
Spanhol-Rosseto, A. [1 ]
Martelli, M. P. [1 ]
Pasqualucci, L. [2 ,3 ]
Quentmeier, H. [4 ]
Grossmann, V. [5 ]
Drexler, H. G. [4 ]
Falini, B. [1 ]
机构：
[1] Univ Perugia, Inst Hematol, Dept Clin & Expt Med, I-06100 Perugia, Italy
[2] Columbia Univ, Inst Canc Genet, New York, NY USA
[3] Columbia Univ, Dept Pathol, New York, NY USA
[4] German Collect Microorganisms & Cell Cultures, DSMZ, Braunschweig, Germany
[5] MLL, Munich, Germany
来源：
LEUKEMIA | 2012年 / 26卷 / 03期
关键词：
ACUTE MYELOID-LEUKEMIA; NUCLEOPHOSMIN;
D O I：
10.1038/leu.2011.238
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：554 / 557
页数：5
相关论文
共 50 条
  • [41] AML typical mutations ( CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular
    Castano-Diez, Sandra
    Lopez-Guerra, Monica
    Zugasti, Ines
    Calvo, Xavier
    Schulz, Felicitas Isabel
    Avendano, Alejandro
    Mora, Elvira
    Falantes, Jose
    Azaceta, Gemma
    Ibanez, Mariam
    Chen, Tzu
    Notano, Cristina
    Amer, Neus
    Palomo, Laura
    Pomares, Helena
    Vila, Jordi
    del Castillo, Teresa Bernal
    Jimenez-Vicente, Carlos
    Esteban, Daniel
    Guijarro, Francesca
    Alamo, Jose
    Cortes-Bullich, Albert
    Torrecillas-Mayayo, Victor
    Triguero, Ana
    Mont-de Torres, Lucia
    Carcelero, Ester
    Cardus, Aina
    Germing, Ulrich
    Betz, Beate
    Rozman, Maria
    Arenillas, Leonor
    Zamora, Lurdes
    Diez-Campelo, Maria
    Xicoy, Blanca
    Esteve, Jordi
    Diaz-Bey, Marina
    BLOOD ADVANCES, 2025, 9 (01) : 39 - 53
  • [42] Nontoxic-dose of Deguelin Induce NPMc plus AML Cell Differentiation by Selectively Targeting Mt NPM1/SIRT1 Instead of HDAC1/3
    Wang, You Ping
    Yi, Sha
    Wen, Lu
    Zhang, Ben Ping
    Zhao, Zichu
    Hu, Jing Yu
    Zhao, Fei
    He, Jing
    Fang, Jun
    Zhang, Chun
    Cui, Guohui
    Chen, Yan
    CURRENT CANCER DRUG TARGETS, 2014, 14 (08) : 685 - 699
  • [43] FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India
    Ghosh, Kanjaksha
    Swaminathan, Suchitra
    Madkaikar, Manisha
    Gupta, Maya
    Kerketta, Lily
    Vundinti, Baburao
    ANNALS OF HEMATOLOGY, 2012, 91 (11) : 1703 - 1712
  • [44] Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations
    Yoon, Jae-Ho
    Kim, Hee-Je
    Jeon, Young-Woo
    Lee, Sung-Eun
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Lee, Seok
    Min, Chang-Ki
    Cho, Seok-Goo
    Kim, Dong-Wook
    Lee, Jong-Wook
    Min, Woo-Sung
    GENES CHROMOSOMES & CANCER, 2015, 54 (08) : 489 - 499
  • [45] Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: A GOELAMS study
    Guieze, Romain
    Cornillet-Lefebvre, Pascale
    Lioure, Bruno
    Blanchet, Odile
    Pigneux, Arnaud
    Recher, Christian
    Bonmati, Caroline
    Fegueux, Nathalie
    Bulabois, Claude-Eric
    Bouscary, Didier
    Vey, Norbert
    Delain, Martine
    Turlure, Pascal
    Himberlin, Chantal
    Harousseau, Jean-Luc
    Dreyfus, Francois
    Bene, Marie C.
    Ifrah, Norbert
    Chevallier, Patrice
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (12) : 1052 - 1056
  • [46] Venetoclax induced complete remission in extramedullary relapse of AML co-harboring NPM1, TET2, and NRAS mutations after haploidentical hematopoietic stem cell transplantation
    Pan, Wenjue
    Zhao, Xiujie
    Shi, Wei
    Jiang, Zhinong
    Xiao, Haowen
    LEUKEMIA & LYMPHOMA, 2020, 61 (11) : 2756 - 2759
  • [47] Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation
    Jentzsch, Madlen
    Grimm, Juliane
    Bill, Marius
    Kuepper, Johannes
    Backhaus, Donata
    Brauer, Dominic
    Schulz, Julia
    Franke, Georg-Nikolaus
    Vucinic, Vladan
    Niederwieser, Dietger
    Platzbecker, Uwe
    Schwind, Sebastian
    BONE MARROW TRANSPLANTATION, 2021, 56 (10) : 2610 - 2612
  • [48] The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial
    Lazenby, M.
    Gilkes, A. F.
    Marrin, C.
    Evans, A.
    Hills, R. K.
    Burnett, A. K.
    LEUKEMIA, 2014, 28 (10) : 1953 - 1959
  • [49] The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China
    Gou, Haimei
    Zhou, Juan
    Ye, Yuanxin
    Hu, Xuejiao
    Shang, Mengqiao
    Zhang, Jingya
    Zhao, Zhenzhen
    Peng, Wu
    Zhou, Yanhong
    Zhou, Yi
    Song, Xingbo
    Lu, Xiaojun
    Ying, Binwu
    TUMOR BIOLOGY, 2016, 37 (06) : 7357 - 7370
  • [50] Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Montalban-Bravo, Guillermo
    Assi, Rita
    Jabbour, Elias
    Ravandi, Farhad
    Kadia, Tapan
    Pierce, Sherry
    Takahashi, Koichi
    Gonzalez, Graciela Nogueras
    Patel, Keyur
    Soltysiak, Kelly A.
    Cortes, Jorge
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    CANCER, 2020, 126 (04) : 765 - 774
12345